FDA Approves New Non-Hormonal Medication for Menopausal Hot Flashes

 

The U.S. Food and Drug Administration has greenlit a new once-daily medication that addresses moderate to severe hot flashes in menopausal women without using hormones, pharmaceutical manufacturer Bayer announced Friday. The drug, elinzanetant, will become available in American markets starting November under the commercial name Lynkuet.

How the Medication Works

The medication functions by inhibiting specific brain chemicals responsible for hot flashes and night sweats—medically termed vasomotor symptoms—affecting menopausal women. Research indicates that over 80% of women experience hot flashes during menopause, making this a widespread concern requiring effective treatment options.

Christine Roth, Bayer’s executive vice president overseeing global product strategy and commercialization, characterized the FDA approval as a significant advancement, marking the company’s first hormone-free solution for alleviating menopausal vasomotor symptoms. She emphasized the necessity for more personalized menopause care approaches, noting that Lynkuet fills a substantial void in available treatment alternatives.

Addressing Treatment Limitations

While hormone therapy provides safe and effective symptom relief for many women experiencing menopause-related issues like hot flashes, certain individuals with specific health conditions or medical histories—including particular cancer diagnoses—receive medical advice against hormone replacement therapies. Medical professionals acknowledge that alternative treatment options become especially valuable for these patients.

Clinical Trial Results

A Phase 3 clinical investigation involving 628 postmenopausal women demonstrated that participants taking elinzanetant for 12 weeks experienced more than 73% reduction in vasomotor symptom frequency. Comparatively, placebo recipients reported only 47% reduction in similar symptoms.

The most frequently observed side effects among women taking the medication included drowsiness, fatigue, and headaches—relatively manageable compared to symptom severity being addressed.

Dr. JoAnn Pinkerton, UVA Health’s midlife health director and emeritus executive director of the North American Menopause Society, commented on the yearlong study findings published last month. The research confirmed initial observations of rapid and substantial reductions in both frequency and severity of hot flashes and night sweats, while providing evidence that these positive effects persisted throughout the year, suggesting potential for sustained long-term relief.

Clinical Significance

Pinkerton emphasized that treatment options for moderate to severe vasomotor symptoms related to menopause have been limited, particularly for those unable or unwilling to pursue hormone therapy. The disruptive nature of severe hot flashes significantly impacts women’s daily activities both professionally and personally, underscoring urgent demand for effective non-hormonal treatments.

Hot flashes manifest as sudden intense heat sensations typically concentrated around the face, chest, and head regions. They frequently trigger intense perspiration and skin flushing lasting several minutes. When occurring during nighttime hours, these episodes are classified as night sweats. Menopausal women may experience them occasionally or multiple times daily, causing extreme lifestyle disruption.

Expanding Treatment Options

Claire Gill, president and founder of the National Menopause Foundation, stressed the importance of women understanding available choices for treating moderate to severe menopause-related hot flashes, noting that this approval further broadens women’s symptom management options.

In 2023, the FDA previously approved fezolinetant, another menopause medication functioning as an alternative to traditional hormone replacement therapies for managing hot flashes. Both fezolinetant and elinzanetant represent pioneering drugs utilizing newly understood brain pathways apparently controlling hot flash occurrence.

Scientific Mechanism

As estrogen levels decline during menopause, nerves within the hypothalamus—a small brain region helping regulate body temperature—become hyperactive, producing excessive chemical signals called neurokinins. Both newly approved medications block cellular receptors where specific neurokinins attach, thereby reducing their capacity to stimulate brain mechanisms causing hot flashes.

Pinkerton noted in Bayer’s announcement that hot flashes, especially severe cases, significantly impact women’s daily functioning. This approval provides healthcare practitioners with new first-line treatment options for moderate to severe menopause-related hot flashes, expanding the therapeutic arsenal available for managing this common menopausal challenge.